Risk of thrombosis in patients with myeloproliferative neoplasms and elevated platelet counts

European Journal of Haematology

Volumn 96, Issue 1, 2016, Pages 5-6

  Wahlin, Anders ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANAGRELIDE; HYDROXYUREA; JANUS KINASE 2;

ACUTE LEUKEMIA; CANCER PATIENT; EDITORIAL; EVENT FREE SURVIVAL; GENE MUTATION; HIGH RISK PATIENT; HUMAN; LEUKOCYTOSIS; LOW RISK PATIENT; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; RISK FACTOR; SICKLE CELL ANEMIA; THROMBOCYTE COUNT; THROMBOSIS; MYELOPROLIFERATIVE DISORDER; NEOPLASM; THROMBOCYTOSIS;

HUMANS; MYELOPROLIFERATIVE DISORDERS; NEOPLASMS; PLATELET COUNT; THROMBOCYTOSIS; THROMBOSIS;

EID: 84954473993     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12585     Document Type: Editorial

References (11)

1. Murphy S, Peterson P, Iland H, Laszlo J. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 1997;34:29-39.
2. Tefferi A, Silverstein MN, Hoagland HC. Primary thrombocythemia. Semin Oncol 1995;22:334-40.
3. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine 1971;50:357-420.
4. Michiels JJ, Kutti J, Stark P, et al. Diagnosis, pathogenesis and treatment of the myeloproliferative disorders essential thrombocythemia, polycythemia vera and essential megakaryocytic granulocytic metaplasia and myelofibrosis. Neth J Med 1999;54:46-62.
5. Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol 2011;29:761-70.
6. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for 404 patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
7. Schwarz J, Penka M, Campr V, et al. Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases - principles and rationale of CZEMP recommendations [In Czech with English abstract]. Vnitř Lék 2011;57:189-213.
8. Schwarz J, Ovesná P, Černá O, et al. Thrombosis in thrombocythemic Ph- myeloproliferations is associated with higher platelet count prior to the event. Results of analyses of prothrombotic risk factors from a registry of patients treated with anagrelide. Eur J Haematol 2015. doi: 10.1111/ejh.12554. [Epub ahead of print]
9. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.
10. Castro O, Nouraie M, Oneal M. Hydroxycarbamide treatment in sickle cell disease: estimates of possible leukaemia risk and of hospitalization survival benefit. Br J Haematol 2014;167:687-91.
11. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia. A 17.5 year follow-up. Am J Hematol 2010;85:403-8.